Dataset Information

Clinical and radiologic outcomes in two patients with multiple sclerosis treated with tocilizumab for COVID-19

ABSTRACT:

Background

Tocilizumab is an interleukin-6 receptor antagonist used to treat COVID-19. A previous case report described development of multiple sclerosis (MS) after treatment with tocilizumab for rheumatoid arthritis, leading to an FDA warning label. We sought to identify patients with multiple sclerosis (MS) who were treated with tocilizumab for coronavirus disease 2019 (COVID-19) and characterize clinical outcomes.

Methods

We electronically identified MS patients who received tocilizumab for COVID-19 from January 2019 to September 2021 and performed retrospective chart review.

Results

Two patients were identified. The patients were both treated with ocrelizumab and had an average disease duration of 10.5 years. Both patients were hospitalized with COVID-19 infection (with WHO COVID-19 severity scales of 5 and 6) and received tocilizumab as treatment for COVID-19. At post-discharge follow-up, EDSS showed no or a mild increase (stable in one patient, and 1 to 2 in the second patient). There was no increase in PDSS score. Follow-up MRI after discharge showed no new T2 lesions, enhancing lesions, or worsening atrophy.

Conclusions

In two MS patients who received tocilizumab for COVID-19, we did not observe significant clinical or radiologic worsening following treatment. Larger scale studies are needed to determine if use of tocilizumab for COVID-19 can provoke relapse or cause MS disease

SUBMITTER: Holroyd K

PROVIDER: S-EPMC8750953 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Background and purposeIn multiple sclerosis (MS), disease-related factors and dysfunctional coping might favor the development of mental distress induced by COVID-19 containment measures. Aim of this study was exploring the relationship between disability, coping strategies, daily life reorganization and neuropsychiatric symptoms in an Italian MS population during the COVID-19 lockdown, in order to identify potentially modifiable factors that could inform clinical management of mental distress in people with MS.MethodsWe explored the relationship between mental distress, disability and coping strategies in the Italian MS population under lockdown. Structural equation modeling was applied to information collected via web survey to identify modifiable factors that could account for mental distress.ResultsA total of 845 participants (497 with MS and 348 controls) were included in the study. The MS group had higher scores than the control group for depression (p = 0.005), but not for anxiety, emotional dyscontrol or sleep disturbances. The structural equation modeling explained 74% of the variance observed in depression score. Within the model, three latent factors were characterized from measured variables: motor disability and cognitive dysfunction contributed to disability (β = 0.509 and β = 0.836; p < 0.001); positive attitude and exercise contributed to active attitude (β = 0.386 and β = 0.297; p < 0.001); and avoidance, social support and watching television contributed to passive attitude (β = 0.301, β = 0.243 and β = 0.212; p < 0.001). With regard to the relationship between latent factors and their influence on depression, disability contributed to passive attitude (β = 0.855; p < 0.001), while both passive and active attitude significantly influenced depression (β = 0.729 and β = -0.456; p < 0.001).ConclusionAs a practical implication of our model, favoring exercise would enhance active attitude and its positive impact on mental well-being while, at the same time, reducing the negative impact of disability on depression, representing a valuable tool in facing COVID-19-related mental distress.